<DOC>
	<DOC>NCT02110394</DOC>
	<brief_summary>Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia</brief_summary>
	<brief_title>Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients with chronic lymphocytic leukemia (CLL) with current or planned first line therapy with Ribomustin Informed Consent Form for personal data handling signed by the program participant Any prior chemotherapy and/or radiotherapy and/or immunotherapy and/or any investigational agent for treatment of CLL Currently participating in any clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment Contraindications for Ribomustin usage in accordance with product label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>observational</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>bendamustine</keyword>
</DOC>